Research ArticleOriginal Article

Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer

Cuicui Zhang, Jing Wang, Xinyue Wang, Zhaoting Meng, Ying Cheng and Kai Li
Cancer Biology & Medicine August 2022, 19 (8) 1249-1258; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0727

Article Figures & Data

Figures

Tables

  • Table 1

    Univariate Cox analysis of progression-free survival and overall survival in patients with small-cell lung cancer

    Clinical characteristicsNumberPFS (days)OS (days)HR (95% CI)P value
    PFSOSPFSOSPFSOSPFSOS
    RBC (×1012/L)–0.451–0.004
    –≤ 3.95
    > 3.95    		–45
    35    		–215 ± 21
    379 ± 41    		(0.261, 0.778)
    Hb (g/L)–0.465–0.023
    –≤ 131
    > 131    		–61
    19    		–248 ± 22
    421 ± 55    		(0.240, 0.899)
    Serum albumin (g/L)–0.548–0.029
    –≤ 38.9
    > 38.9    		–24
    57    		–193 ± 33
    326 ± 30    		(0.319, 0.939)
    CEA (μg/L)–2.406–0.002
    –≤ 11.82
    > 11.82    		–59
    22    		–339 ± 33
    182 ± 20    		(1.374, 4.213)
    NSE (μg/L)–3.253–< 0.001
    –≤ 26.42
    > 26.42    		–26
    55    		–444 ± 48
    210 ± 19    		(1.742, 6.077)
    Blood glucose (mmol/L)1.705–0.028–
    ≤ 5.395
    > 5.395    		–46
    35    		–177 ± 22
    116 ± 14    		–(1.058, 2.747)
    Plasma globulin (g/L)1.793–0.042–
    ≤ 28.36
    > 28.36    		–40
    28    		–205 ± 33
    126 ± 16    		–(1.020, 3.152)
    WBC (×109/L)1.694–0.034–
    ≤ 5.135
    > 5.135    		–37
    43    		–181 ± 22
    119 ± 14    		–(1.041, 2.758)
    Neutrophils (×109/L)1.6992.0230.0320.008
    ≤ 3.52
    > 3.52    		38
    42    		183 ± 22
    115 ± 14    		326 ± 26
    239 ± 32    		(1.048, 2.753)(1.198, 3.415)
    GGT (U/L)2.2552.1990.0020.004
    ≤ 39.5
    > 39.5    		36
    >42    		201 ± 25
    105 ± 14    		347 ± 31
    230 ± 31    		(1.337, 3.804)(1.287, 3.757)
    INR2.3782.3440.0020.003
    ≤ 1.045
    > 1.045    		60
    21    		171 ± 18
    89 ± 14    		332 ± 31
    187 ± 32    		(1.337, 3.804)(1.503, 4.273)
    PT (s)1.9662.2180.0110.008
    ≤ 11.25
    > 11.25    		30
    51    		197 ± 28
    121 ± 13    		364 ± 41
    239 ± 25    		(1.171, 3.302)(1.227, 4.009)
    NLR5.8822.198< 0.0010.003
    ≤ 7.75
    > 7.75    		≤ 4.03
    > 4.03    		74
    6    		45
    35    		160 ± 15
    44 ± 17    		363 ± 36
    209 ± 27    		(2.417, 4.314)(1.310, 3.686)
    AST (U/L)1.9042.0980.0210.004
    ≤ 19.15
    > 19.15    		≤ 26.75
    > 26.75    		25
    56    		53
    28    		211 ± 35
    123 ± 12    		350 ± 33
    193 ± 29    		(1.103, 3.287)(1.252, 3.516)
    LDH (U/L)1.8352.4400.0140.002
    ≤ 254.65
    > 254.65    		≤ 210
    > 210    		51
    29    		34
    46    		181 ± 21
    104 ± 17    		406 ± 45
    213 ± 21    		(1.132, 2.973)(1.404, 4.240)
    Fbg (g/L)1.8173.7200.026< 0.001
    ≤ 3.395
    > 3.395    		≤ 4.645
    > 4.645    		26
    55    		59
    22    		200 ± 29
    126 ± 15    		348 ± 31
    147 ± 24    		(1.073, 3.075)(2.111, 6.557)

    “−” indicates an index that is not a significant factor. PFS, progression-free survival; OS, overall survival; HR, hazard ratio; RBC, red blood cell; Hb, hemoglobin; CEA, carcinoembryonic antigen; NSE, neuron-specific enolase; WBC, white blood cell; GGT, glutamyl transpeptidase; INR, international normalized ratio; PT, prothrombin time; NLR, neutrophil to lymphocyte ratio; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; Fbg, fibrinogen.

    • Table 2

      Univariate Cox analysis of PFS and OS with adverse events in the anlotinib group

      AEsNumberPFS (days)OS (days)HRP value
      PFSOSPFSOS
      Oral mucositis0.368–0.009–
       Yes
       No      		15
      66      		261 ± 40
      131 ± 14      		–(0.175, 0.776)
      Leukopenia0.551–0.044–
       Yes
       No      		19
      62      		210 ± 37
      128 ± 12      		–(0.308, 0.983)
      Elevated NLR1.790–0.020–
       Yes
       No      		30
      51      		106 ± 16
      175 ± 19      		–(1.096, 2.923)
      Hypophosphatemia0.283–0.015–
       Yes
       No      		8
      73      		293 ± 63
      132 ± 13      		(0.102, 0.781)
      Hypercholesterolemia–0.476–0.029
       Yes
       No      		20
      61      		414 ± 58
      237 ± 19      		(0.244, 0.928)
      Elevated lipase–2.214–0.040
       Yes
       No      		20
      61      		172 ± 35
      311 ± 28      		(1.035, 4.738)
      Hypoproteinemia–2.882–0.004
       Yes
       No      		10
      71      		133 ± 33
      316 ± 27      		(1.396, 5.950)
      Elevated amylase–3.745–0.008
       Yes
       No      		5
      76      		134 ± 19
      307 ± 27      		(1.415, 9.909)
      Elevated GGT1.7202.1390.0480.008
       Yes
       No      		21
      60      		107 ± 20
      164 ± 18      		180 ± 32
      331 ± 30      		(1.005, 2.943)(1.224, 3.738)

      “−” means this index is not a significant factor. AEs, adverse events; TSH, Thyroid stimulating hormone.

      • Table 3

        Multivariate Cox regression analysis of PFS and OS in patients with SCLC

        PFSBSEWaldSigExp (B)95% CI
        NLR (≤ 7.75, > 7.75)2.3060.64812.6730.00010.0302.81835.691
        LDH (≤ 254.65 U/L, > 254.65 U/L)0.7360.3753.8470.0502.0871.0014.352
        Elevated GGT (Yes/no)0.7920.3046.7880.0092.2071.2174.003
        Hypophosphatemia (Yes/no)–1.2230.5834.4770.0340.2910.0930.913
        OSBSEWaldSigExp(B)95% CI
        AST (≤ 26.75 U/L, > 26.75 U/L)0.7810.3136.2170.0132.1841.1824.037
        NSE (≤ 26.42 ng/mL, > 26.42 ng/mL)1.0650.3917.4390.0062.9021.3506.240
        Fbg (≤ 4.645 g/L, > 4.645 g/L)0.8280.4233.8300.0502.2881.0005.241
        Elevated GGT (Yes, no)1.3440.39711.4780.0013.8361.7628.348
        Hypercholesterolemia (Yes, no)–0.9410.3616.7780.0090.3900.1920.793
      Back to top

      In this issue

      Print
      Download PDF
      Email Article
      Citation Tools

      Jump to section

      Keywords